Net sales grew 11.2% to CHF 428.4 million, but net income declined 1.9% to CHF 103.6 million as margins narrowed due to higher costs. Major investments in new production capacity were completed, positioning the company for robust medium-term demand in small molecule APIs.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.